Biotech firm upbeat despite £10.1m loss

MANCHESTER-based live biotheraputics specialist 4D Pharma has made a pre-tax loss of £10.1m after completing a year of acquisition and Stock Market placings which have raised £64.8m.

The company is at the forefront of research into treatment of irritable bowel syndrome and Crohn’s Disease among children as won approval to start trails for both.

It has also initiated a research programme in conjunction with University College Cork to look at the potential effect of bacteria on conditions such as autism, depression and anxiety.

In its final results for the year ended December 31 Duncan Peyton, chief executive officer of 4D, said: “The year has seen the evolution of the group’s discovery projects and research methodology.
 
“We now have 15 therapeutic programmes in development covering the areas of autoimmunity, central nervous system (CNS) disorders and cancer as well as a number of candidates progressing through clinical trials. We remain excited by the prospects for the coming period.”